Authors:
, , , , , , and
Authors:
and
Balázs Döme
Balázs Döme
IV. Tüdőgyógyászati Osztály, Országos Korányi TBC és Pulmonológiai Intézet, 1529, Budapest, Pihenő u. 1.
Tumorbiológiai Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Search for other papers by Balázs Döme in
Current site
Google Scholar
PubMed
Tumorbiológiai Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Search for other papers by Balázs Döme in
Current site
Google Scholar
PubMed
Melinda Magyar
Melinda Magyar
XI. Tüdőgyógyászati Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Tumorbiológiai Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Search for other papers by Melinda Magyar in
Current site
Google Scholar
PubMed
Tumorbiológiai Osztály, Országos Korányi TBC és Pulmonológiai Intézet, Budapest
Search for other papers by Melinda Magyar in
Current site
Google Scholar
PubMed
Absztrakt
Bár a sebészi reszekció, a platina-alapú kemoterápiás kombinációk és a sugárterápia javítottak a túlélési eredményeken, a nem kissejtes tüdőrák (NSCLC) túlélésének növekedési görbéje plató fázisához érkezett. Az új terápiás lehetőségek közé tartoznak a molekuláris célzott terápiák, ezeken belül a tumorok érhálózatára ható szerek. Jelenleg a bevacizumab – mely egy a vaszkuláris endotheliális növekedési faktor (VEGF) elleni rekombináns, monoklonális antitest – a klinikai fejlesztések legelőrehaladottabb stádiumban lévő gyógyszere. Ugyanakkor más célzott érellenes szerek is – beleértve a VDA-kat (vascular disrupting agents) és különféle kis molekulájú tirozinkináz-inhibitorokat – reménykeltők voltak a preklinikai és klinikai vizsgálatokban. Jelen közleményünkben áttekintjük az NSCLC-ben önmagukban vagy kemoterápiával kombináltan alkalmazható antivaszkuláris terápiás stratégiákat.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. A Aicher C Heeschen C Mildner-Rihm et al.2003 Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells Nat Med 9 1370 1376.
-
2. Amin DN , Bielenberg DR, Lifshits E, et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 18 Mar, 2008 (Epub ahead of print).
-
3. T Asahara T Murohara A Sullivan et al.1997 Isolation of putative progenitor endothelial cells for angiogenesis Science 275 964 967.
-
4. P Baluk H Hashizume DM McDonald 2005 Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 102 111.
-
5. LE Benjamin D Golijanin A Itin et al.1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165.
-
6. P Bonomi 2002 Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer Semin Oncol 29 78 86.
-
7. T Browder CE Butterfield BM Kräling et al.2000 Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878 1886.
-
8. LA Byers JV Heymach 2007 Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer Clin Lung Cancer 8 Suppl 2 S79 85.
-
9. DJ Chaplin GR Pettit SA Hill 1999 Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate Anticancer Res 19 189 195.
-
10. JJ Chen PL Yao A Yuan et al.2003 Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer Clin Cancer Res 9 729 737.
-
11. M Decaussin H Sartelet C Robert et al.1999 Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival J Pathol 188 369 377.
-
12. C Delbaldo S Michiels N Syz et al.2004 Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis JAMA 292 470 484.
-
13. P Delmotte B Martin M Paesmans et al.2002 VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis Rev Ma Respir 19 577 584.
-
14. B Dome J Dobos J Tovari et al.2008 Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease Cytometry A 73 186 193.
-
15. B Dome MJ Hendrix S Paku et al.2007 Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications Am J Pathol 170 1 15.
-
16. B Dome J Timar J Dobos et al.2006 Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer Cancer Res 66 7341 7347.
-
17. A Dowlati R Gray DH Johnson et al.2006 Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel + bevacizumab in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 24S 7027.
-
18. J Drevs U Zirrgiebel CI Schmidt-Gersbach et al.2005 Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials Ann Oncol 16 558 565.
-
19. DG Duda RK Jain CG Willett 2007 Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers J Clin Oncol 25 4033 4042.
-
20. LM Ellis 2004 Epidermal growth factor receptor in tumor angiogenesis Hematol Oncol Clin North Am 18 1007 1021.
-
21. G Fontanini L Boldrini S Chinè et al.1999 Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas Br J Cancer 79 363 369.
-
22. G Fontanini S Vignati L Boldrini et al.1997 Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma Clin Cancer Res 3 861 865.
-
23. E Fox JM Maris BC Widemann et al.2006 A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors Clin Cancer Res 12 4882 4887.
-
24. K Fujimoto T Abe NL Müller et al.2003 Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis Radiology 227 786 793.
-
25. S Fujita S Nagamachi R Nishii et al.2006 Relationship between cancer cell proliferation, tumour angiogenesis and 201Tl uptake in non-small cell lung cancer Nucl Med Commun 27 989 997.
-
26. G Furstenberger R von Moos R Lucas et al.2006 Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer Br J Cancer 94 524 531.
-
27. E Garanger D Boturyn P Dumy 2007 Tumor targeting with RGD peptide ligands – design of new molecular conjugates for imaging and therapy of cancers Anticancer Agents Med Chem 7 552 558.
-
28. U Gatzemeier G Blumenschein F Fosella et al.2006 Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma J Clin Oncol 24 18S 7002.
-
29. JA Gollob S Wilhelm C Carter SL Kelley 2006 Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 392 406.
-
30. MS Gordon K Margolin M Talpaz et al.2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850.
-
31. GD Goss S Laurie F Shepherd et al.2007 Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group J Clin Oncol 25 18S 7649.
-
32. R Govindan N Page D Morgensztern et al.2006 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539 4544.
-
33. J Guo K Higashi Y Ueda et al.2006 Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas J Nucl Med 47 419 425.
-
34. IE Haines GL Miklos A Rossi et al.2008 Paclitaxel plus bevacizumab for metastatic breast cancer N Eng J Med 358 1637 1638.
-
35. H Han JF Silverman TS Santucci et al.2001 Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis Ann Surg Oncol 8 72 79.
-
36. KR Hande A Hagey J Berlin et al.2006 The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study Clin Cancer Res 12 2834 2840.
-
37. RS Herbst VJ O'Neill L Fehrenbacher et al.2007 Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 4743 4750.
-
38. J Heymach L Paz-Ares F De Braud et al.2007 Randomized phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as first-line treatment for advanced non-small cell lung cancer (NSCLC) J Clin Oncol 25 18S 7544.
-
39. JV Heymach BE Johnson D Prager et al.2007 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer J Clin Oncol 25 4270 4277.
-
40. W Hilbe S Dirnhofer F Oberwasserlechner et al.2004 CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J Clin Pathol 57 965 969.
-
41. A Hirata S Ogawa T Kometani et al.2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2554 2560.
-
42. JW Ho RW Pang C Lau et al.2006 Significance of circulating endothelial progenitor cells in hepatocellular carcinoma Hepatology 44 836 843.
-
49. J Hu F Bianchi M Ferguson et al.2005 Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer Oncogene 24 1212 1219.
-
50. CA Hudis 2005 Clinical implications of antiangiogenic therapies Oncology (Williston Park) 19 4 Suppl 3 26 31.
-
51. H Hurwitz L Fehrenbacher W Novotny et al.2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342.
-
52. C Igreja M Courinha AS Cachaco et al.2007 Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients Haematologica 92 469 477.
-
53. A Iwasaki M Kuwahara Y Yoshinaga T Shirakusa 2004 Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC Eur J Cardiothorac Surg 25 443 448.
-
54. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989.
-
55. RK Jain DG Duda JW Clark JS Loeffler 2006 Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 24 40.
-
56. DH Johnson L Fehrenbacher WF Novotny et al.2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191.
-
57. F Kabbinavar HI Hurwitz L Fehrenbacher et al.2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65.
-
58. NB Leighl L Paz-Arez JL Douillard et al.2005 Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 J Clin Oncol 23 2831 2839.
-
59. B Li EE Sharpe AB Maupin et al.2006 VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization FASEB J 20 1495 1497.
-
60. X Li M Tjwa L Moons et al.2005 Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors J Clin Invest 115 118 127.
-
61. Y Li ZG Yang TW Chen et al.2008 Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT Lung Cancer 61 44 53.
-
62. B Liu T Barrett P Choyke et al.2006 A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 17119.
-
63. J Llevadot S Murasawa Y Kureish et al.2001 HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells J Clin Invest 108 399 405.
-
64. F Loupakis A Falcone G Masi et al.2007 Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity J Clin Oncol 25 1816 1818.
-
65. SH Ma K Xu ZW Xiao et al.2007 Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression Clin Imaging 31 165 177.
-
66. C Manegold J von Pawel P Zatloukal et al.2007 Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 J Clin Oncol 25 18S 7514.
-
67. R Masood J Cai T Zheng et al.2001 Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors Blood 98 1904 1913.
-
68. M Massa V Rosti I Ramajoli et al.2005 Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia J Clin Oncol 23 5688 5695.
-
69. HJ Mauceri NN Hanna MA Beckett et al.1998 Combined effects of angiostatin and ionizing radiation in antitumour therapy Nature 394 287 291.
-
70. MJ McKeage 2006 Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) J Clin Oncol 24 18S 7102.
-
71. KD Miller CJ Sweeney GW Sledge Jr 2001 Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 1195 1206.
-
72. MA Moore K Hattori B Heissig et al.2001 Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1 Ann NY Acad Sci 938 36 47.
-
73. R Murata DW Siemann J Overgaard MR Horsman 2001 Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid Radiat Res 156 503 509.
-
74. RB Natale D Bodkin R Govindan et al.2006 ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part double-blind randomized phase II trial J Clin Oncol 24 18S 7000.
-
75. AM O'Farrell TJ Abrams HA Yuen et al.2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 3605.
-
76. M Olivero M Rizzo R Madeddu et al.1996 Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas Br J Cancer 74 1862 1868.
-
77. Y Ozawa NH Sugi T Nagasu et al.2001 E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo Eur J Cancer 37 2275 2282.
-
78. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108.
-
79. E Passalidou M Trivella N Singh et al.2002 Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas Br J Cancer 86 244 249.
-
80. DM Patterson GJ Rustin 2007 Vascular damaging agents Clin Oncol (R Coll Radiol) 19 443 456.
-
81. AM Petit J Rak MC Hung et al.1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1523 1530.
-
82. F Pezzella U Pastorino E Tagliabue et al.1997 Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am J Pathol 151 1417 1423.
-
83. DG Pfister DH Johnson CG Azzoli et al.2004 American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330 353.
-
84. A Pircher CM Kähler S Skvortsov et al.2008 Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance Oncol Rep 19 345 352.
-
85. JM Provenzale 2007 Imaging of angiogenesis: clinical techniques and novel imaging methods AJR Am J Roentgenol 188 11 23.
-
86. M Relf S LeJeune PA Scott et al.1997 Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 963 969.
-
87. GJ Riely VA Miller 2007 Vascular endothelial growth factor trap in non small cell lung cancer Clin Cancer Res 13 4623 4627.
-
88. T Sánchez-Elsner LM Botella B Velasco et al.2002 Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways J Biol Chem 277 43799 43808.
-
89. A Sandler R Gray MC Perry et al.2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550.
-
90. M Santimaria G Moscatelli GL Viale et al.2003 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 571 579.
-
91. M Santoro RM Melillo F Carlomagno et al.2002 Molecular mechanisms of RET activation in human cancer Ann NY Acad Sci 963 116 121.
-
92. JH Schiller D Harrington CP Belani et al.2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98.
-
93. JH Schiller T Larson SI Ou et al.2007 Efficacy and safety of axitinib (AG-013736; AG) in patients with advanced non-small cell lung cancer (NSCLC): A phase II trial J Clin Oncol 25 18S 7507.
-
94. FH Seeger J Haendeler DH Walter et al.2005 p38 mitogen-activated protein kinase downregulates endothelial progenitor cells Circulation 111 1184 1191.
-
95. G Serini D Valdembri F Bussolino 2006 Integrins and angiogenesis: a sticky business Exp Cell Res 312 651 658.
-
96. T Seto M Higashiyama H Funai et al.2006 Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer Lung Cancer 53 91 96.
-
97. Y Shaked A Ciarrocchi M Franco et al.2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 1785 1787.
-
98. FA Shepherd J Rodrigues Pereira T Ciuleanu et al.2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132.
-
99. M Shiraga S Yano A Yamamoto et al.2002 Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines Cancer Res 62 5967 5973.
-
100. DW Siemann MC Bibby GG Dark et al.2005 Differentiation and definition of vascular-targeted therapies Clin Cancer Res 11 416 420.
-
101. DW Siemann E Mercer S Lepler AM Rojiani 2002 Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 1 6.
-
102. BG Siim AE Lee S Shalal-Zwain et al.2003 Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Cancer Chemother Pharmacol 51 43 52.
-
103. MA Socinski S Novello JM Sanchez et al.2006 Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial J Clin Oncol 24 18S 7001.
-
104. K Strehlow N Werner J Berweiler et al.2003 Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation Circulation 107 3059 3065.
-
105. CJ Sweeney KD Miller SE Sissons et al.2001 The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors Cancer Res 61 3369 3372.
-
106. T Tamura H Minami Y Yamada et al.2006 A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors J Thoracic Oncol 1 1002 1009.
-
107. F Tanaka S Ishikawa K Yanagihara et al.2002 Expression of angiopoietins and its clinical significance in non-small cell lung cancer Cancer Res 62 7124 7129.
-
108. N Thatcher A Chang P Parikh et al.2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537.
-
109. Tímár J , Döme B. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 2008 (in press).
-
110. S Verma MA Kuliszewski SH Li et al.2004 C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease Circulation 109 2058 2067.
-
111. JM Vignaud B Marie N Klein et al.1994 The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer Cancer Res 54 5455 5463.
-
112. SR Wedge DJ Ogilvie M Dukes et al.2002 ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655.
-
113. A Wierzbowska T Robak A Krawczynska et al.2005 Circulating endothelial cells in patients with acute myeloid leukemia Eur J Haematol 75 492 497.
-
114. SM Wilhelm M Carter L Tang et al.2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109.
-
115. CG Willett Y Boucher E di Tomaso et al.2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147.
-
116. CG Willett Y Boucher DG Duda et al.2005 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol 23 8136 8139.
-
118. JC Yang L Haworth RM Sherry et al.2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434.
-
119. KW Yee A Hagey S Verstovsek et al.2005 Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 11 6615 6624.
-
120. Y Yokoyama M Dhanabal AW Griffioen et al.2000 Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth Cancer Res 60 2190 2196.
-
121. H Zhang V Vakil M Braunstein et al.2005 Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood 105 3286 3294.
-
122. L Zhang J Chen Y Ke et al.2005 Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance World J Surg Oncol 3 68.
-
123. PP Zheng WC Hop TM Luider et al.2007 Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas Ann Neurol 62 40 48.
| Magyar Onkológia | |
|---|---|
| Language | Hungarian |
| Size | |
| Year of Foundation |
1956 |
| Publication Programme |
|
| Volumes per Year |
|
| Issues per Year |
|
| Founder | Magyar Onkológusok Társasága |
| Founder's Address |
H-1122 Budapest, Hungary Ráth György u. 7-9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 0025-0244 (Print) |
| ISSN | 2060-0399 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Jun 2024 | 32 | 0 | 0 |
| Jul 2024 | 58 | 0 | 0 |
| Aug 2024 | 28 | 0 | 0 |
| Sep 2024 | 79 | 0 | 0 |
| Oct 2024 | 149 | 0 | 0 |
| Nov 2024 | 184 | 0 | 0 |
| Dec 2024 | 93 | 2 | 0 |
Author:
Author:
Author:
Authors:
, , , , , , , , and
Authors:
, , , , , , , , , , , , , , , , , , , , and
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory